Abstract:Asymptomatic gene carriers and clinically affected ADO2 subjects have the same ClCN7 mutation. We examined osteoclastic bone resorption in vitro as well as osteoclast formation, several markers, acid secretion, and cytoskeletal structure. We found that ADO2 expression results from osteoclast specific properties. Introduction: Autosomal dominant osteopetrosis type II (ADO2) is a heritable osteosclerotic disorder that results from heterozygous mutations in the ClCN7 gene. However, of those individuals with a ClCN7 mutation, one third are asymptomatic gene carriers who have no clinical, biochemical, or radiological manifestations. Disease severity in the remaining two thirds is highly variable. Materials and methods: Human peripheral blood mononuclear cells were isolated and differentiated into osteoclasts by stimulation with hRANKL and human macrophage-colony stimulating factor (hM-CSF). Study subjects were clinically affected subjects, unaffected gene carriers, and normal controls (n = 6 in each group). Pit formation, TRACP staining, RANKL dose response, osteoclast markers, acid secretion, F-actin ring, and integrin alpha(v)beta3 expression and co-localization were studied. Results: Osteoclasts from clinically affected subjects had severely attenuated bone resorption compared with those from normal controls. However, osteoclasts from unaffected gene carriers displayed similar bone resorption to those from normal controls. In addition, the resorption lacunae from both unaffected gene carriers and normal controls appeared much earlier and spread much more rapidly than those from clinically affected subjects. As time progressed, the distinction between clinically affected subjects and the other two groups increased. No significant difference was found in acidic secretion or osteoclast formation between the three groups. Osteoclast cytoskeletal organization showed no difference between the three groups but there was low cellular motility in clinically affected subjects. Conclusions: Osteoclasts from the unaffected gene carriers, in contrast to those from the clinically affected subjects, functioned normally in cell culture. This finding supports the hypothesis that intrinsic osteoclast factors determine disease expression in ADO2. Further understanding of this mechanism is likely to lead to the development of new approaches to the treatment of clinically affected patients.

SLC4A2 Deficiency Causes a New Type of Osteopetrosis

Novel CLCN7 Mutations Cause Autosomal Dominant Osteopetrosis Typeii and Intermediate Autosomal Recessive Osteopetrosis

Enhanced but Hypofunctional Osteoclastogenesis in an Autosomal Dominant Osteopetrosis Type II Case Carrying a C.1856c>t Mutation in CLCN7.

Two Novel Mutations of CLCN7 Gene in Chinese Families with Autosomal Dominant Osteopetrosis (type II)

Identification of the CLCN7 gene mutations in two Chinese families with autosomal dominant osteopetrosis (type II)

Novel Mutations of CLCN7 Cause Autosomal Dominant Osteopetrosis Type II (ADOII) and Intermediate Autosomal Recessive Osteopetrosis (ARO) in Seven Chinese Families

A Novel Compound Heterozygous Mutation of the CLCN7 Gene is Associated with Autosomal Recessive Osteopetrosis

Identification of TCIRG1 and CLCN7 Gene Mutations in a Patient with Autosomal Recessive Osteopetrosis

Clinical and genetic diagnosis of autosomal dominant osteopetrosis type II in a Chinese family: A case report

The Virulence Gene and Clinical Phenotypes of Osteopetrosis in the Chinese Population: Six Novel Mutations of the CLCN7 Gene in Twelve Osteopetrosis Families

Novel mutations of CLCN7 cause autosomal dominant osteopetrosis type II (ADO-II) and intermediate autosomal recessive osteopetrosis (IARO) in Chinese patients

Autosomal Dominant Osteopetrosis Type II Resulting from a De Novo Mutation in the CLCN7 Gene: A Case Report

Clinical and molecular characterization of five Chinese patients with autosomal recessive osteopetrosis

Mise En Évidence De Deux Nouvelles Mutations Du Gène CLCN7 Par L’étude De Trois Familles Chinoises Atteintes D’une Ostéopétrose Autosomique Dominante De Type II

Gain-of-function variants in CLCN7 cause hypopigmentation and lysosomal storage disease

Heterozygous Mutation of SLC34A1 in Patients with Hypophosphatemic Kidney Stones and Osteoporosis: a Case Report.

Disease status in autosomal dominant osteopetrosis type 2 is determined by osteoclastic properties

Osteomesopyknosis associated with a novel ALOX5 variant that impacts the RANKL pathway

Chloride channel 7-related osteopetrosis

The A242t Mutation In The Low-Density Lipoprotein Receptor-Related Protein 5 Gene In One Chinese Family With Osteosclerosis

A Novel Variant in CLCN7 Regulates the Coupling of Angiogenesis and Osteogenesis